Advanced Filters
noise

Neoplasms Clinical Trials

A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 13,633 clinical trials
F Feng'e Li

An Exploratory Clinical Study to Evaluate the Safety, Tolerability, Immune Response and Preliminary Efficacy of LM103 Injection in Combination With PD-1 in Patients With Advanced Solid Tumours

This is an exploratory clinical study evaluating the safety, tolerability, immune response and preliminary efficacy of LM103 Injection in combination with PD-1 in patients with advanced solid tumours. The research treatment includes LM103 injection, IL-2 therapy, PD-1 therapy,fludarabine and cyclophosphamide.

18 - 75 years of age All Phase N/A

Treatment of Advanced and Metastatic Solid Tumors With MIL97

This is a Phase 1, global, multi-center, open-label, multiple-dose, first-in-human study of MIL97 to evaluate the safety, tolerability, pharmacokinetics, biomarkers and efficacy in subjects with advanced or metastatic solid tumor. The study consists of a dose escalation phase and a dose expansion phase. An accelerated titration design (cohorts 1-2 only) …

18 years of age All Phase 1
L Li Yu

Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T

The efficacy of advanced pancreatic cancer and gastric cancer needs to be further improved. Claudin is a kind of integrin membrane protein in the tight junction between epithelium and endothelium, which is highly expressed in gastric cancer and pancreatic cancer. Preclinical studies suggest that Claudin18.2CAR-T can effectively improve the remission …

18 - 75 years of age All Phase N/A

A Study of JNJ-87890387 for Advanced Solid Tumors

The purpose of this study is to determine recommended phase 2 dose(s) (RP2Ds) of JNJ-87890387 and to determine the safety of JNJ-87890387 at the RP2D(s).

18 years of age All Phase 1

A Study for HSK39775 in Participants With Solid Tumors

This research is designed to determine if HSK39775 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

18 years of age All Phase 1/2

A Study of CS23546 in Subjects With Advanced Tumors

The primary objectives of this study are to characterize the safety and tolerability of CS23546 and to evaluate the pharmacokinetic (PK) characteristics and recommended phase 2 dose (RP2D) of CS23546 in subjects with advanced tumors.

18 years of age All Phase 1
Y Yeon Hee Park, MD, Ph.D

Study of DM5167 in Patients With Advanced Solid Tumors

DM5167 is a second-generation of PARP inhibitor that selectively targets the PARP-1 enzyme. This results in less haematological toxicity and a high level of safety. The aim of the study is to assess the safety and tolerability of DM5167 in patients with advanced solid tumors not respond to other treatments.

19 years of age All Phase 1
H Hongkun Cai

A Study of AL58805 in Patients With Advanced Tumors

This Phase I clinical trial is a dose-escalation, multicenter study in patients with advanced solid tumors. It includes tolerance studies of sequential multiple oral doses of AL58805 and pharmacokinetic studies of single and multiple doses, analyzing the tolerance range of multiple doses, observing the maximum tolerated dose (MTD) and dose-limiting …

18 years of age All Phase 1
A Abhishek Chatterjee, MD

Intensity Modulated PrOton Therapy in Pediatric BRain Tumors (IMPORT)

Children diagnosed with benign or low-grade brain tumors often require radiation therapy to control their disease. While radiation can be effective, traditional techniques using X-rays (photon-based radiotherapy) expose healthy brain tissue to radiation, potentially leading to long-term side effects like memory loss, learning difficulties, hormone imbalances, hearing problems, and a …

6 - 16 years of age All Phase N/A
X Xu Ruihua, MD

Study of CM518D1 in Patients With Advanced Solid Tumors

This is an interventional study to assess the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of CM518D1 in patients with advanced solid tumors.

18 - 75 years of age All Phase 1/2

Simplify language using AI